Dr Tomer Bronshtein, head of research at Bonus BioGroup, has been developing cellular therapies to treat acute respiratory distress in Covid-19 patients.  In their trials of ‘MesenCure’, which uses mesenchymal cells, the treatment has been shown to dampen the hyper-inflammatory response in the acute phase of the disease as well as promote the healing of injured lung tissue, dramatically improving survival rates and reducing the length of hospital stays.  Whilst MesenCure is being developed as a treatment in the acute phase, the data suggests that its efficacy can also reduce the chances of developing Long Covid.  We talk to Dr Bronshtein about their results, potential future applications, and the need for caution as we all battle to find a potential cure.Living with Long Covid? How was your week?Website - https://www.tlcsessions.net/Twitter - @SessionsTlc https://twitter.com/sessionstlcInsta - @tlcsessions https://www.instagram.com/tlcsessions